Vivesto AB Asset Resilience Ratio
Vivesto AB asset resilience ratio. Vivesto AB (VIVE) has an Asset Resilience Ratio of 12.89% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIVE days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vivesto AB (2014–2025)
Asset resilience ratio of Vivesto AB from 2014 to 2025. This chart shows how Vivesto AB's Asset Resilience Ratio has changed over time. Read Vivesto AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vivesto AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VIVE asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr21.73 Million | 12.89% |
| Total Liquid Assets | Skr21.73 Million | 12.89% |
Asset Resilience Insights
- Moderate Liquidity: Vivesto AB has 12.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Vivesto AB Industry Peers by Asset Resilience Ratio
Compare Vivesto AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Vivesto AB Asset Resilience Ratio by Year (2014–2025)
Vivesto AB asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Vivesto AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.05% | Skr72.00K ≈ $7.75K |
Skr149.04 Million ≈ $16.04 Million |
-18.18pp |
| 2024-12-31 | 18.23% | Skr31.51 Million ≈ $3.39 Million |
Skr172.88 Million ≈ $18.60 Million |
-14.74pp |
| 2023-12-31 | 32.97% | Skr72.75 Million ≈ $7.83 Million |
Skr220.67 Million ≈ $23.75 Million |
-4.42pp |
| 2022-12-31 | 37.39% | Skr133.05 Million ≈ $14.32 Million |
Skr355.88 Million ≈ $38.30 Million |
+22.35pp |
| 2021-12-31 | 15.04% | Skr89.36 Million ≈ $9.62 Million |
Skr594.31 Million ≈ $63.96 Million |
-13.60pp |
| 2020-12-31 | 28.64% | Skr247.28 Million ≈ $26.61 Million |
Skr863.54 Million ≈ $92.93 Million |
+5.35pp |
| 2019-12-31 | 23.28% | Skr234.08 Million ≈ $25.19 Million |
Skr1.01 Billion ≈ $108.19 Million |
+23.28pp |
| 2018-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr646.38 Million ≈ $69.56 Million |
-3.88pp |
| 2015-12-31 | 3.88% | Skr20.01 Million ≈ $2.15 Million |
Skr515.58 Million ≈ $55.48 Million |
-5.87pp |
| 2014-12-31 | 9.75% | Skr50.15 Million ≈ $5.40 Million |
Skr514.57 Million ≈ $55.38 Million |
-- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more